PSDV Share Price

Open 1.82 Change Price %
High 1.83 1 Day -0.07 -3.85
Low 1.73 1 Week -0.05 -2.78
Close 1.75 1 Month -0.06 -3.31
Volume 185179 1 Year -1.03 -37.05
52 Week High 4.25
52 Week Low 1.50
PSDV Important Levels
Resistance 2 1.84
Resistance 1 1.80
Pivot 1.77
Support 1 1.70
Support 2 1.66
NASDAQ USA Most Active Stocks
NVDA 100.49 -9.27%
JBHT 97.31 -1.05%
AREX 2.96 -1.99%
OZRK 55.54 1.02%
FNSR 34.15 0.12%
AGNC 19.64 0.72%
EA 86.65 -0.84%
FNFG 10.18 -0.20%
PRFZ 118.04 -0.80%
DELL 13.86 0.22%
More..
NASDAQ USA Top Gainers Stocks
ECTE 0.18 50.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
ZAZA 0.06 20.00%
JAKK 5.70 12.87%
LINE 0.18 12.50%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

pSivida Corp. (NASDAQ: PSDV)

PSDV Technical Analysis 4
As on 23rd Feb 2017 PSDV Share Price closed @ 1.75 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.73 & Sell for SHORT-TERM with Stoploss of 1.79 we also expect STOCK to react on Following IMPORTANT LEVELS.
PSDV Target for February
1st Target up-side 2.02
2nd Target up-side 2.2
3rd Target up-side 2.38
1st Target down-side 1.5
2nd Target down-side 1.32
3rd Target down-side 1.14
PSDV Other Details
Segment EQ
Market Capital 36343336.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.psivida.com
PSDV Address
PSDV
400 Pleasant Street
Watertown, MA 02472
United States
Phone: 617-926-5000
Fax: 617-926-5050
Interactive Technical Analysis Chart pSivida Corp. ( PSDV NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on pSivida Corp.
PSDV Business Profile
pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. As of June 30, 2011, the Company is focused on the treatment of chronic eye diseases utilizing its cored technology systems, Durasert and BioSilicon. Its product candidate ILUVIEN, for the treatment of diabetic macular edema (DME) is under review by the United States Food and Drug Administration (FDA). Its product candidate ILUVIEN, for the treatment of diabetic macular edema (DME) is under review by the United States Food and Drug Administration (FDA). The Company�s two FDA-approved products provide sustained release drug delivery to treat other back-of-the-eye diseases. An investigator-sponsored trial is ongoing for an injectable bioerodible insert delivering latanoprost designed to treat glaucoma and ocular hypertension and an investigator-sponsored Investigational New Drug opened for an injectable insert of the same design as ILUVIEN designed to treat posterior uveitis.